Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ferritin light chain pseudogene 19 (FTLP19) is classified as a pseudogene, meaning it is a segment of genomic DNA that is similar to known genes but is generally non-functional and does not encode a functional protein[4]. It is not recognized as coding for an active protein, receptor, enzyme, or other therapeutic target class, and there is no evidence that it plays a direct role in biological processes or disease pathways[4]. FTLP19 is related by sequence to the ferritin light chain gene (FTL), which is involved in iron storage, but FTLP19 itself does not have a known functional product or clinical significance[4]. If you intended the canonical functional ferritin light chain, see FTL/HGNC:3999, but FTLP19 is a pseudogene only[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ferritin light chain pseudogene 19 (FTLP19).